Bristol-Myers Squibb Co Earnings - Q3 2026 Analysis & Highlights
Bristol Myers Squibb reported 7% third-quarter revenue growth, continued double-digit growth in its Growth Portfolio, multiple late-stage pipeline advances, and raised full-year EPS guidance; discussion also covered commercial launches, capital allocation, and the expected 2027 Eliquis impact.
Key financial results
Total revenue increased 7% year over year to approximately $13.1 billion in Q3 2026.
Growth Portfolio revenue rose 12% to $7.7 billion, while Legacy Portfolio revenue increased 1%, with Eliquis growth offsetting declines from generic entry across the rest of the portfolio.
Gross margin was 68.4%, reflecting product mix and, to a lesser extent, a one-time contract-termination expense; the call did not provide a year-over-year margin comparison.
Operating expenses were $4.1 billion; the company cited productivity initiatives as helping reduce expenses in identified areas while preserving investment flexibility.
The effective tax rate was 14.1%, reflecting jurisdictional earnings mix and the impact of an acquired in-process R&D charge.
Diluted non-GAAP EPS was $1.35, including a $0.58-per-share impact from acquired in-process R&D and licensing income.
Bristol Myers Squibb held approximately $13 billion in cash equivalents and marketable securities at September 30 and generated approximately $4.2 billion in operating cash flow during the quarter.
Business segment results
The company reported results for its Growth and Legacy Portfolios, rather than providing separate operating-segment profit figures in the call. Growth Portfolio sales increased 12% to $7.7 billion, and Legacy Portfolio sales increased 1%.
Oncology: Opdivo revenue declined 6% to approximately $2.4 billion, primarily due to conversion to Qvantig in the U.S. and Europe; Qvantig revenue was $334 million, up 28% sequentially and annualizing at over $1.3 billion.
Oncology: Reblozyl grew 22% to $750 million, reflecting first-line MDS-associated anemia uptake; Breyanzi grew 48% to $526 million, supported by demand in U.S. and international markets.
Oncology: Opdualag delivered another quarter of strong double-digit growth, supported by global demand and its position as a standard of care in first-line U.S. melanoma.
Cardiovascular: Eliquis revenue was approximately $4.7 billion, up 26%, driven by net price, demand, and market-share gains; Q4 sales were expected to be affected by European loss of exclusivity, partly offset by U.S. growth.
Cardiovascular: Camzyos revenue increased 42% to $420 million, supported by new patient starts and deeper community penetration; Q3 revenue was affected sequentially by a typical inventory drawdown, expected to normalize in Q4.
Immunology: Sotyktu global revenue grew 25%; the company cited support for its recent adult psoriatic arthritis indication and anticipated year-end Phase 3 lupus readouts.
Neuroscience: Cobenfy revenue grew 33% to $57 million; inventory destocking offset increased demand, and management expected revenue to track prescription volume more closely going forward.
Management said eight Growth Portfolio medicines were each annualizing at more than $1 billion based on Q3 sales.
Capital allocation
Business development remained a capital-allocation priority, with the company evaluating opportunities in therapeutic areas where it has relevant scientific capabilities and seeking deals that are strategically and financially sound; management said deal size was not the determining factor.
Management said it was actively evaluating partnerships, licensing deals, and, where appropriate, acquisitions, while maintaining financial discipline and focusing on sustainable growth.
The company reiterated its commitment to the dividend as part of its approach to returning cash to shareholders.
Management cited approximately $13 billion of cash on hand as providing strategic flexibility.
The call did not provide a specific share-repurchase, debt-repayment, or capital-expenditure guidance figure. The company did, however, announce a planned approximately $2.3 billion Houston manufacturing campus and a more than $170 million Indiana radiopharmaceutical facility.
Industry trends and dynamics
Management described continuing need for effective, well-tolerated disease-modifying therapies in IPF and PPF, noting that tolerability and effects on how patients feel, function, and survive are important considerations.
The company estimated the IPF/PPF market at $4 billion today and said it could nearly double as newer treatments create a larger second-line switch and add-on market.
Management cited substantial treatment challenges in these diseases: it said 50% of patients do not survive five years and half discontinue treatment within 12 months.
For GEP-NETs, the company estimated approximately 18,000 U.S. diagnoses annually and said roughly 70% of patients progressing from Lutathera go on to need another therapy.
Management characterized Cobenfy’s potential Alzheimer’s disease psychosis market as fundamentally different from schizophrenia, citing approximately 7 million diagnosed U.S. Alzheimer’s patients and an estimated 30% to 50% with psychosis.
For Alzheimer’s disease psychosis, management said there are no currently approved treatments and described existing off-label antipsychotic use and safety concerns in elderly patients with dementia.
Competitive landscape
Management said Qvantig is gaining adoption across tumor types and cited a three-minute subcutaneous injection as improving practice efficiency; the company was tracking toward converting at least 30% to 40% of its IV business, with conversion then tracking toward the high end of that range.
Management said Camzyos became the only FDA-approved therapy for pediatric patients with obstructive HCM after an expanded-indication approval in September.
Management positioned Zenbexus as the first approved CELMoD, citing positive physician feedback on its MRD results and simplicity of use, and said the commercial focus was to establish it as an option that can replace Revlimid- and Pomalyst-based regimens over time.
Management said admilparant’s safety and tolerability could differentiate it in IPF and PPF, where gastrointestinal tolerability and cough can be difficult to manage; it also cited discontinuations due to adverse events similar to placebo in the ALOFT study.
Management said RYZ101 could address patients progressing after Lutathera, where it described no approved treatments today, and expressed a goal of establishing it as the standard of care after Lutathera.
In small-cell lung cancer, management acknowledged impressive frontline IMDELLTRA data and said it expected room for multiple agents as patients are subtyped and treated across lines of therapy.
Management described Cobenfy as not associated with certain adverse events linked to D2 antipsychotics and said it does not carry a boxed warning; it also identified dose titration and management of nausea and vomiting as areas requiring physician and patient education.
Macroeconomic environment
The call did not provide specific commentary on inflation, tariffs, recession, trade conditions, or a broader macroeconomic outlook; management’s outlook focused on company performance, products, and portfolio impacts.
Growth opportunities and strategies
Management’s priorities included sustaining Growth Portfolio momentum, translating pipeline progress into filings, approvals, and launches, and improving R&D speed and operational productivity.
The company said it was targeting $2 billion in productivity efficiencies by the end of 2027 and described productivity efforts as a means to align expenses while continuing to invest in growth opportunities.
Management cited AI as an investment area across discovery, development, commercialization, manufacturing, and enabling functions. It identified goals including a 20% to 30% reduction in drug-testing timelines and cutting in half the time from target selection to lead-molecule identification.
The company reported positive registrational or late-stage results for Zenbexus, admilparant, RYZ101, and arlo-cel, and said it was preparing to advance programs toward regulatory steps and launches.
Management highlighted upcoming development milestones, including Milvexian secondary stroke prevention and Sotyktu lupus Phase 3 data before year-end, and additional Milvexian, Cobenfy, and golcadomide data in 2027.
The company said it was building manufacturing capacity for future medicines through a planned Houston campus with flexibility across small molecules, biologics, and antibody-drug conjugates, and an Indiana radiopharmaceutical facility.
Bristol Myers Squibb said RayzeBio could serve as an IND engine, with multiple INDs expected over the next five years; management also cited radiopharmaceutical programs beyond RYZ101 in liver and prostate cancer.
For Zola-cel, management said the clinical program was paused for review, that it had identified a reagent-selection and activation change as the root cause of an issue, and that it had adjusted the process and was working with authorities toward restarting the program.
Management said it was pursuing external innovation where it fit the company strategically and scientifically, particularly where it could strengthen near-term growth or contribute to sustained growth later in the decade.
Financial Guidance and Outlook
Bristol Myers Squibb raised its full-year 2026 revenue guidance based on year-to-date results and its outlook for the remainder of the year; the call did not state the revised revenue range.
The company’s 2026 non-GAAP EPS guidance is $6.35 to $6.55, including the previously cited $0.58-per-share impact from acquired in-process R&D and licensing income. Excluding those Q3 items, management said the guidance midpoint would have increased by approximately $0.15 per share.
Management maintained its projections for gross margin, operating expenses, and tax rate, while slightly lowering the expense level on the other-income-and-expense line.
Full-year Legacy Portfolio revenue was expected to decrease 3% to 5%, while full-year Eliquis revenue growth was still expected to be 20% to 25%.
Management anticipated an approximately $1.5 billion to $2 billion Eliquis step-down in 2027 and said it expected productivity efficiencies of $2 billion by the end of 2027.
Management said the Growth Portfolio’s performance and the late-stage pipeline supported confidence entering 2027, while emphasizing continued expense discipline and investment in growth opportunities.
